Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design by Ima Paydar et al.
July 2016 | Volume 6 | Article 1671
Original research
published: 20 July 2016
doi: 10.3389/fonc.2016.00167
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Adam Paul Dicker, 
Thomas Jefferson University, USA
Reviewed by: 
Chandan Guha, 
Albert Einstein College 
of Medicine, USA  
Daniel E. Spratt, 
University of Michigan, USA
*Correspondence:
Sean P. Collins  
spc9@gunet.georgetown.edu
Specialty section: 
This article was submitted to 
Radiation Oncology, 
a section of the journal 
Frontiers in Oncology
Received: 08 March 2016
Accepted: 28 June 2016
Published: 20 July 2016
Citation: 
Paydar I, Cyr RA, Yung TM, Lei S, 
Collins BT, Chen LN, Suy S, 
Dritschilo A, Lynch JH and Collins SP 
(2016) Proctitis 1 Week after 
Stereotactic Body Radiation Therapy 
for Prostate Cancer: Implications 
for Clinical Trial Design. 
Front. Oncol. 6:167. 
doi: 10.3389/fonc.2016.00167
Proctitis 1 Week after stereotactic 
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Leonard N. Chen1, Simeng Suy1, Anatoly Dritschilo1, John H. Lynch2 and Sean P. Collins1*
1 Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA, 2 Department of Urology, 
Georgetown University Hospital, Washington, DC, USA
Background: Proctitis following prostate cancer radiation therapy is a primary determi-
nant of quality of life (QOL). While previous studies have assessed acute rectal morbidity 
at 1 month after stereotactic body radiotherapy (SBRT), little data exist on the prevalence 
and severity of rectal morbidity within the first week following treatment. This study 
reports the acute bowel morbidity 1 week following prostate SBRT.
Materials and methods: Between May 2013 and August 2014, 103 patients with 
clinically localized prostate cancer were treated with 35–36.25 Gy in five fractions using 
robotic SBRT delivered on a prospective clinical trial. Bowel toxicity was graded using 
the Common Terminology Criteria for Adverse Events version 4.0 (CTCAEv.4). Bowel 
QOL was assessed using the EPIC-26 questionnaire bowel domain at baseline, 1 week, 
1 month, and 3 months. Time-dependent changes in bowel symptoms were statisti-
cally compared using the Wilcoxon signed-rank test. Clinically significant change was 
assessed by the minimally important difference (MID) in EPIC score. This was defined as 
a change of 1/2 standard deviation (SD) from the baseline score.
results: One-hundred and three patients with a minimum of 3  months of follow-up 
were analyzed. The cumulative incidence of acute grade 2 gastrointestinal (GI) toxic-
ity was 23%. There were no acute ≥ grade 3 bowel toxicities. EPIC bowel summary 
scores maximally declined at 1 week after SBRT (−13.9, p < 0.0001) before returning 
to baseline at 3 months after SBRT (+0.03, p = 0.94). Prior to treatment, 4.9% of men 
reported that their bowel bother was a moderate to big problem. This increased to 
28.4% (p < 0.0001) 1 week after SBRT and returned to baseline at 3 months after SBRT 
(0.0%, p = 0.66). Only the bowel summary and bowel bother score declines at 1 week 
met the MID threshold for clinically significant change.
conclusion: The rate and severity of acute proctitis following prostate SBRT peaked 
at 1 week after treatment and returned to baseline by 3 months. Toxicity assessment at 
1 week can therefore minimize recall bias and should aid in the design of future clinical 
trials focused on accurately capturing and minimizing acute morbidity following SBRT.
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inTrODUcTiOn
Proctitis after prostate cancer radiation therapy is a primary 
determinant of quality of life (QOL) and remains an ongoing 
clinical challenge. Acute radiation proctitis commonly peaks 
during conventionally fractionated treatment (1–4) and resolves 
a few weeks to months after the completion of therapy (5, 6). 
Patients with acute radiation proctitis describe symptoms of 
bowel frequency and urgency, rectal pain, or rectal bleeding (7). 
Four to 50% of patients treated with conventionally fractionated 
intensity-modulated radiation therapy (IMRT) develop grade 
2 or greater acute proctitis (8–11). The risk of acute radiation 
proctitis is dependent upon the rectal volume exposed to a 
high radiation dose (12, 13) as well as the fractionation schema 
(14). In an attempt to reduce radiation related bowel morbidity, 
pretreatment dietary intervention (15) or enemas (16) have been 
utilized with only modest improvements. Several studies have 
demonstrated that acute rectal symptoms may also be the best 
predictor of late proctitis (17–19).
Patient-reported outcomes have become an increasingly reli-
able tool when comparing the relative morbidity of the different 
treatment options for localized prostate cancer (5). In such a 
situation, it is important to select the most appropriate time point 
and recall period for symptom assessment as these time points 
will vary depending on the evaluated symptom and its acute or 
chronic nature. Not surprisingly, the rate of memory decay is 
impacted by the severity and temporal pattern of the symptom, 
with recall of mild and transient symptoms decaying faster than 
those of severe and persistent symptoms (20). Thus, assessment 
of toxicities too far after their occurrence may result in underes-
timation of their overall incidence in a given treatment group, 
and the differences between treatment groups may therefore be 
artificially minimized (20). An early time point with a short recall 
period, therefore, is generally preferable for acute and transient 
symptoms such as acute radiation proctitis (21).
Early results suggest that prostate SBRT with 35–40  Gy in 
four to five fractions confers rates of biochemical relapse-free 
survival and late rectal toxicity which are comparable to alterna-
tive radiation modalities (22–24). However, little data exist on 
acute bowel morbidity prior to the 1-month interval, creating a 
potential for recall bias in patient-reported outcomes. The goal 
of this study is to accurately delineate the acute rectal morbidity 
of this treatment modality in the setting of clinically localized 
prostate cancer.
MaTerials anD MeThODs
Patient selection and characteristics
Patients eligible for study inclusion had clinically localized pros-
tate cancer treated on a prospectively conducted IRB-approved 
institutional QOL protocol (IRB 12-1175). Risk groups were 
defined using the D’Amico criteria. Other patient and treatment 
characteristics, such as age, race, Charlson Comorbidity Index 
(CCI), prostate volume, pretreatment PSA, T stage, Gleason score, 
hormone treatment, use of anticoagulants and/or antiplatelets, 
and dose, were acquired from the medical records. Baseline QOL 
was assessed using the EQ-5D, which contains five general health 
questions (EQ-5D index) and a visual analog scale (EQ VAS), 
with higher values indicating better QOL (25).
sBrT Treatment Planning and Delivery
The CyberKnife robotic radiosurgical system (Accuray Inc., 
Sunnyvale, CA, USA) was used to deliver SBRT treatments 
(26). One week prior to simulation, gold fiducial markers were 
placed within the prostate under ultrasound guidance. For 
treatment planning, thin cut (1.25 mm) CT images as well as 
high-resolution magnetic resonance images were acquired and 
fused. The clinical target volume (CTV) encompassed the pros-
tate and proximal seminal vesicles. The planning target volume 
(PTV) included a 3 mm (inferior, superior, and posterior) or 
5 mm (anterior and lateral) expansion around the CTV. Pelvic 
lymph nodes were not treated. To account for interfraction and 
intrafraction prostate motion, fiducial-based tracking was used. 
Thirty-five or 36.25 Gy was delivered in five fractions (7–7.25 Gy 
per fraction) to the PTV. The rectum was contoured as a solid 
structure from the anus (at the level of the ischial tuberosities 
on axial CT images) to the rectosigmoid flexure. Dose-volume 
histogram (DVH) analysis was performed using Multiplan 
(Accuray Inc., Sunnyvale, CA, USA) inverse treatment plan-
ning. No more than 1 cc of rectal volume was to receive 36 Gy. 
Assuming an α/β of 3 Gy for late bowel complications, this is 
biologically equivalent to approximately 74  Gy administered 
in 2 Gy fractions. Other rectal DVH constraints included the 
following: <50% rectal volume was to receive 50% of the pre-
scribed dose, <20% to receive 80% of the dose, <10% to receive 
90% of the dose, and <5% to receive 100% of the dose. Typical 
dose distributions have been previously described (27). To 
optimize the prostate–rectal wall distance and to reduce intra-
fraction prostate motion, patients were instructed to adhere to 
a low-residual diet and undergo enemas prior to simulation and 
treatment delivery (16).
Follow-Up and statistical analysis
Physician-reported acute bowel toxicity was prospectively 
assessed at the initial and each subsequent follow-up visit. The 
National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events version 4.0 (CTCAEv.4) was used to assign 
toxicity scores. Acute toxicity was defined as having occurred 
up to 3 months following completion of prostate SBRT. Grade 
1 was defined by the CTCAE criteria as rectal discomfort with 
intervention not indicated. Grade 2 was defined as symptoms 
(e.g., rectal discomfort, passing blood, or mucus), medical 
intervention indicated, limiting instrumental activities of daily 
living (ADL). In this study, patients were generally assigned a 
grade 2 for requiring a new medication (i.e., steroid suppository 
or anti-diarrheal). Grade 3 was defined as severe symptoms, fecal 
urgency, or stool incontinence, limiting self care ADL. In this 
study, patients were generally assigned grade 3 for requiring a 
surgical intervention. Cumulative likelihood estimates for acute 
≥ grade 2 bowel toxicity were determined using the Kaplan–Meier 
method.
Acute proctitis was also prospectively reported by patients 
using the bowel domain of the Expanded Prostate Index 
Composite (EPIC)-26 questionnaire at baseline (1 hour prior to 
TaBle 1 | Patient and treatment specifics.
Patients N = 103 (%) n
Age (years) Median 69 (48–85)
<60 11.7 12
60–69 44.7 46
70–79 35.0 36
≥80 8.7 9
Race White 56.3 58
Black 28.2 29
Other 15.5 16
Charlson comorbidity index CCI = 0 61.2 63
CCI = 1 30.1 31
CCI ≥ 2 8.7 9
Prostate volume (cc) Median 36 (13–125)
Pre-txt PSA (ng/ml) Median 7 (2.2–50)
≤10 75.7 78
>10 and ≤20 16.5 17
>20 7.8 8
T stage T1c 63.1 65
T2a 20.4 21
T2b 12.6 13
T2c 2.9 3
T3 1.0 1
Gleason score 3 + 3 = 6 32.0 33
3 + 4 = 7 34.0 35
4 + 3 = 7 20.4 21
3 + 5 = 8 1.0 1
4 + 4 = 8 10.7 11
4 + 5 = 9 1.9 2
Risk groups (D’Amico) Low 19.4 20
Intermediate 65.0 67
High 15.5 16
Hormone treatment Yes 16.5 17
No 83.5 86
Use of anticoagulants/
antiplatelets
Yes 36.9 38
No 63.1 65
Dose (Gy) 35 47.6 49
36.25 52.4 54
TaBle 2 | Prevalence of cTc graded gastrointestinal (gi) toxicities at 
each follow-up.
Follow-up time point Day 7 
(%)
Month 1 
(%)
Month 3 
(%)
Toxicity grade
Bowel frequency/urgency 0 51 65 89
1 26 32 11
2 23 3 0
Proctitis 0 79 85 98
1 21 15 2
2 0 0 0
Rectal bleeding 0 86 91 97
1 14 9 3
2 0 0 0
Highest GI 0 43 54 84
1 34 43 16
2 23 3 0
TaBle 3 | Pretreatment quality of life scores.
Mean sD MiD
Baseline eQ-5D
EQ-5D index 0.908 0.089 0.045
EQ VAS 80.2 14.87 7.4
Baseline ePic-26 domain
Bowel summary 92.6 12.99 6.5
Bowel bother 87.4 23.19 11.6
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the first fraction) and at 1 week, 1 month, and 3 months follow-
ing the final SBRT treatment (28). Patients completed a paper 
 questionnaire at baseline, 1 month, and 3 months. However, to 
minimize the burden of frequent clinic visits, the 1 week ques-
tionnaire was completed via a nursing phone interview. The recall 
period, the time patients are asked to consider when answering 
questions, was 1 week at the 1 week time point and 1 month for all 
others. The EPIC-26 bowel domain includes five questions related 
to individual symptoms (questions 6a–e: urgency, frequency, 
pain, bloody stool, incontinence) and one question (question 7) 
related to overall bother (degree of annoyance caused by bowel 
symptoms).
The EPIC bowel domain and its encompassing questions are 
scored on a range from 0 to 100, with higher values representing 
more favorable bowel symptoms. For each EPIC question, the 
responses were grouped into three clinically relevant categories 
(no problem, very small to small problem, and moderate to big 
problem). To statistically compare changes between time points, 
the levels of responses were assigned a score. The significance 
of the mean changes in the scores was then assessed by using 
the Wilcoxon signed-rank test, generating two-sided p values. 
Clinically significant change was assessed by the minimally 
important difference (MID) in EPIC score, and this was defined 
as a change of 1/2 standard deviation (SD) from the baseline (29).
resUlTs
From May 2013 to August 2014, 103 prostate cancer patients were 
treated on an institutional prospective SBRT QOL protocol. They 
were ethnically diverse, with 56.3% being of Caucasian ancestry. 
The median age was 69  years (range, 48–85  years) (Table  1). 
By D’Amico classification, 19.4% patients were low risk, 65.0% 
intermediate risk, and 15.5% high risk. A small percentage of 
patients (16.5%) also underwent androgen deprivation therapy 
(ADT). Thirty-seven percent also utilized anticoagulants and/
or antiplatelets. Approximately half (52%) of the patients were 
treated with 36.25  Gy in five 7.25  Gy fractions, and 48% were 
treated with 35 Gy in five 7 Gy fractions.
The prevalence of CTCAE-graded GI toxicities at each 
follow-up time point is illustrated in Table  2, with individual 
symptoms as well as the highest GI toxicity per patient depicted 
independently. Bowel frequency and urgency was the most com-
mon toxicity, with 23% of patients experiencing grade 2 toxicity 
at seven days after treatment (Table 2). The cumulative incidence 
FigUre 2 | Overall bowel bother score (baseline and following sBrT; 
question 7 of ePic-26). Dashed lines represent the minimally important 
difference (MID) defined as the threshold for clinically significant change in 
scores (1/2 SD above and below the baseline). Higher EPIC score values 
(range 0–100) indicate a more satisfactory health-related QOL. Vertical lines 
at each time point represent 95% confidence interval.
FigUre 1 | average ePic bowel summary scores (baseline and 
following sBrT; question 6a-e of ePic-26). Dashed lines represent the 
minimally important difference (MID) defined as the threshold for clinically 
significant change in scores (1/2 SD above and below the baseline). Higher 
EPIC score values (range 0–100) indicate a more satisfactory health-related 
QOL. Vertical lines at each time point represent 95% confidence interval.
TaBle 4 | changes in ePic bowel summary and overall bowel bother scores following sBrT for prostate cancer.
Domain 1-week post treatment (n = 102) 1-month post treatment (n = 100) 3-month post treatment (n = 82)
Mean score 
change from 
baseline
sD p Mean score 
change from 
baseline
sD p Mean score 
change from 
baseline
sD p
Bowel summary −13.9 12.99 p < 0.0001* −4.5 13.18 p < 0.0001* +0.03 8.74 p = 0.9370
Bowel bother −23.9 34.05 p < 0.0001* −9.1 24.01 p = 0.0002* −1.8 17.2 p = 0.6567
*Indicates statistical significance.
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of acute grade 2 GI toxicity was 23%. There were no acute grade 
3 or greater toxicities.
Table  3 shows the baseline EQ-5D, EPIC bowel summary, 
and EPIC bowel bother scores. Table 4 shows mean changes in 
EPIC summary scores from baseline to 3 months of follow-up. 
A transient decline in the EPIC bowel summary score occurred 
at 1 week (mean change,  −13.9; p < 0.0001). However, the EPIC 
bowel summary score returned to baseline 3 months after SBRT 
(mean change from baseline, +0.03; p = 0.9370) (Table 4). While 
bowel summary score declines at 1 week and 1 month were both 
statistically significant when compared to baseline (p < 0.0001 for 
both), only the change at 1 week remained below the threshold 
for clinically significant change (MID = 6.5) (Figure 1). Table 3 
shows that the mean baseline EPIC bowel bother score was 87.4. 
Bowel bother worsened after treatment, with a reduction in 
mean score to 63.5 at 1 week (mean change, −23.9; p < 0.0001) 
(Table  4). Bowel bother declines at 1  week and 1  month were 
statistically significant (p < 0.0001 and p = 0.0002, respectively); 
however, only the change at 1 week met the threshold for clini-
cally significant change (MID = 11.6) (Figure 2). The EPIC bowel 
bother score returned to near baseline at 3 months after SBRT 
(mean change from baseline, −1.8; p = 0.6567) (Table 4).
Baseline moderate to big bowel symptoms including urgency, 
frequency, and incontinence were 4.9%, 3.9%, and 1.9%, respec-
tively, with 1% experiencing bloody stool and 1.9% abdominal, 
pelvic, or rectal pain (Table  5). All bowel symptoms increased 
at 1 week post-SBRT but returned to near baseline at 3 months 
(Table  5). At baseline, 31% of patients reported some level of 
annoyance due to bowel symptoms, with 4.9% of patients feeling 
that bowel function was a moderate to big problem (Table  6). 
This is consistent with other studies reporting baseline overall 
bowel problems in up to 3% of patients undergoing IMRT, proton 
therapy, or brachytherapy (5, 30). At 1 week following SBRT, 28% 
of patients felt that their bowel function was a moderate to big 
problem, and this number declined to 0% by 3 months. Radar plot 
distribution of individual bowel symptoms at baseline and follow-
ing SBRT shows the majority of the patients experienced bowel 
urgency and frequency at 1 week after SBRT, and by 3 months all 
symptoms subsided to that of the baseline level (Figure 3).
DiscUssiOn
What is the appropriate time point and recall period to 
assess acute bowel symptoms following prostate SBRT such 
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that clinically meaningful symptoms are captured fully and 
accurately? Early results with prostate SBRT (35–40  Gy in 
four to five fractions) have suggested very low rates of acute 
rectal toxicity (22–24). However, such studies did not collect 
outcomes until 1 month after treatment. As a result of the short 
SBRT treatment course (1–2 weeks), acute symptoms develop 
near the end of treatment and last for only a few days, causing 
potential underestimation of the actual rates of acute morbid-
ity when the assessment is made at one month. On the other 
hand, the length and burdensome nature of the EPIC-26 would 
preclude patients from filling out a daily questionnaire. A time 
point with a 7 day recall period was chosen for this study as 
TaBle 5 | Patient-reported bowel symptoms after prostate sBrT 
as recorded by the ePic-26 questions 6a (urgency to have a bowel 
movement), 6B (frequency of bowel movements), 6c (losing control of 
your stools), 6D (bloody stools), and 6e (abdominal, pelvic, or rectal 
pain).
start Day 7 Month 1 Month 3
Bowel urgency
No problem (%) 71.8 52.0 56.0 65.5
Very small-small problem (%) 23.3 22.5 40.0 29.9
Moderate-big problem (%) 4.9 25.5 4.0 4.6
p Value <0.0001* 0.0056* 0.1128
Bowel frequency
No problem (%) 78.6 55.9 59.0 79.3
Very small-small problem (%) 17.5 19.6 37.0 19.5
Moderate-big problem (%) 3.9 24.5 4.0 1.1
p Value <0.0001* 0.0015* 1.00
incontinence
No problem (%) 93.2 84.3 86.0 93.1
Very small-small problem (%) 4.9 9.8 12.0 6.9
Moderate-big problem (%) 1.9 5.9 2.0 0.0
p Value 0.0066* 0.1531 1.00
Bloody stools
No problem (%) 94.2 86.3 89.0 94.3
Very small-small problem (%) 4.9 8.8 10.0 4.6
Moderate-big problem (%) 1.0 4.9 1.0 1.0
p Value 0.0182* 0.2439 0.8203
Pain (abdominal, pelvic, or rectal)
No problem (%) 84.5 72.5 77.0 90.8
Very small-small problem (%) 13.6 13.7 20.0 8.0
Moderate-big problem (%) 1.9 13.7 3.0 1.1
p Value 0.0004* 0.0775 0.1294
N 103 102 100 87
*Indicates statistical significance.
TaBle 6 | Patient-reported overall bowel bother after prostate sBrT as 
recorded by the ePic-26 question 7.
start Day 7 Month 1 Month 3
Bowel bother
No problem (%) 68.9 37.3 43.0 66.7
Very small-small problem (%) 26.2 34.3 51.0 33.3
Moderate-big problem (%) 4.9 28.4 6.0 0.0
p Value <0.0001* 0.0002* 0.6583
N 103 102 100 87
*Indicates statistical significance.
providing a balance between the limits of elderly patients’ 
memory and the burden of filling out time-consuming ques-
tionnaires. Thus, to the best of our knowledge, this is the first 
study to specifically address proctitis 1  week following the 
completion of prostate SBRT.
Indeed, our results demonstrate that overall acute rectal 
morbidity is near its maximum several days after the comple-
tion of SBRT, improves by 1 month, and returns to baseline by 
approximately 3  months. Here, we report that 23% of patients 
experienced ≥ grade 2 acute GI toxicity at 1 week, an incidence 
which is comparable to those reported for conventional fraction-
ated radiation therapy (9, 10). However, even mild bowel toxicity 
can adversely affect quality of life (31). Therefore, we utilized the 
EPIC questionnaire as a sensitive QOL instrument to further 
assesses bowel quality of life (32–34). The temporal pattern seen 
in acute bowel QOL and toxicity following SBRT for prostate 
cancer demonstrated here is comparable to the pattern reported 
following conventionally fractionated radiotherapy (34–36). The 
bowel QOL score is at its lowest near the end of treatment, but 
quickly recovers to the approximate baseline level by 3 months 
after treatment. Specifically, in our series, most moderate to big 
problems were seen at 1  week after SBRT, with approximately 
25% of patients reporting moderate to big problems with bowel 
urgency and/or frequency.
Our prior paper reported the prevalence, severity, and overall 
incidence of bowel frequency and urgency, rectal pain, and 
rectal bleeding at 1  month following SBRT (24). Because the 
recall period for the EPIC-26 is 1  month, it was assumed that 
the 1 month follow-up questionnaire captures bowel morbidity at 
1 week. However, based on the results of the current study, it can 
be concluded that the 1 month questionnaire under-ascertained 
acute rectal symptoms. Future symptom management trials 
assessing the impact of interventions on acute bowel morbidity 
following SBRT should therefore consider including toxicity 
measurement at 1 week after SBRT.
Currently, there are limited approaches to manage radia-
tion proctitis. Medical treatments such as antidiarrheals or 
steroid suppositories are commonly administered in response 
to symptoms with modest benefit (16). Unfortunately, these 
agents cannot be used as prophylaxis due to significant side 
effects such as anal irritation and constipation, highlighting 
the necessity for ongoing clinical research directed at symptom 
management. In the future, to increase the distance between 
the prostate and the rectum and thus reduce rectal radiation 
exposure, we plan to investigate the utilization of absorbable 
spacers in the context of prostate SBRT (37). Symptom con-
trol trials assessing the clinical value of these spacers should 
evaluate the impact of spacers on acute bowel morbidity 1 week 
following treatment.
Moreover, a reduction in acute bowel morbidity may improve 
long-term clinical outcomes. Following conventionally fraction-
ated radiation therapy, non-healing acute proctitis has been 
shown to directly progress to chronic late bowel morbidity (38). 
It has been hypothesized that permanent damage occurs when a 
large area of rectal mucosa is injured and subsequently unable to 
fully repair (39). If true, reducing the incidence and severity of 
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